Last reviewed · How we verify
Intralipid, 20% Intravenous
At a glance
| Generic name | Intralipid, 20% Intravenous |
|---|---|
| Also known as | i.v. fat emulsion |
| Sponsor | Hospital for Special Surgery, New York |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction (PHASE2)
- Low Dose Fat-Induced Insulin Resistance (EARLY_PHASE1)
- Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses (PHASE2)
- Intralipid® 20% for Reversal of Local Anesthetics (PHASE4)
- Does Intralipid Infusion Can Reverse the Spinal Anesthesia Effect in Day Case Surgery? (NA)
- Role of Intralipid in Management of Organophosphorus Poisoning (PHASE2, PHASE3)
- A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses (PHASE2)
- Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intralipid, 20% Intravenous CI brief — competitive landscape report
- Intralipid, 20% Intravenous updates RSS · CI watch RSS
- Hospital for Special Surgery, New York portfolio CI